• 제목/요약/키워드: Topiramate

검색결과 23건 처리시간 0.017초

Valproate 치료를 받는 간질환아에서 체중증가와 영향을 주는 인자 (Valproate-associated weight gain and potential predictors in children with epilepsy)

  • 장국찬;김은영;노영일;문경래;박상기
    • Clinical and Experimental Pediatrics
    • /
    • 제50권5호
    • /
    • pp.484-488
    • /
    • 2007
  • 목 적 : VPA치료를 받는 소아 청소년기 간질환자들에서 체중증가의 비율과 체중증가에 관련되는 예측 인자를 알아보고자 하였다. 방 법 : 2001년 1월 1일부터 2004년 12월 31일까지 VPA 치료를 받기 시작한 8세에서 17세까지의 환아를 대상으로 하였다. 제외기준은 치료 시작후 6개월 이내 치료가 중단된 경우, 체중에 영향을 주는 약물을 병합한 경우 등이었다. VPA 치료 시작시와 치료 시작 후 한번이상 재방문시에 체중과 신장이 측정되어 두 시점에서 BMI를 측정한 후 대상 환아들을 백분위수에 따라 4가지의 BMI군으로 분류하여 BMI군의 상승여부를 조사했으며 체중증가율을 의미하는 BMI difference를 계산하였다. 또한 체중증가에 영향을 미치는 여러 인자들을 회귀분석 하였다. 결 과 : 전체 36명중 총 8명의 환아가 VPA 치료전보다 최소 한 단계 이상의 BMI군의 상승변화를 보였으며 대상환아의 72.2%에서 체중증가(BMI difference의 증가)를 나타내었다. 신경정신 발달(P=0.017), 간질 형태(P=0.001), 투약기간(P=0.035)은 통계적으로 유의한 체중증가에 영향을 미치는 예측인자였다. 결 론 : VPA는 간질 환아에서 체중증가를 유발하며 정상 신경정신 발달, 전신 발작형 간질, 12개월 이상의 투약기간이 체중증가의 예측인자로 생각된다. 따라서 VPA 치료를 받는 소아 간질환자에서는 치료 시작 전에 VPA로 인한 체중증가의 가능성을 고려하여 치료 받는 중 BMI의 지속적인 감시측정이 필요할 것으로 생각된다.

음주운전자 275명 혈액 중 마약류 및 남용약물의 분석 (Distribution of Abused Drugs in 275 Alcohol-positive Blood Samples of Korean Driver)

  • 최혜영;이주선;최상길;김은미;김재균;김영운;임미애;정희선
    • 약학회지
    • /
    • 제52권2호
    • /
    • pp.137-146
    • /
    • 2008
  • Even though driving under the influence of drug (DUID) is a worldwide problem, we, Korea has no regulation system yet except for alcohol, and there are little cases reported related to DUID. In order to investigate the type of abused drugs for drivers in Korea, we tried to analyze controlled and non-controlled drugs in alcohol-positive blood samples. 275 whole bloods, which were positive for alcohol on the roadside test, were collected from the police for two months ($Nov.{\sim}Dec.$ 2006). The analytical strategy was constituted of three steps: First, alcohol in blood samples were confirmed and quantified by gas chromatography. Second, controlled drugs were screened by $Evidence_{investigator}\;^{TM}$ (Randox, U.K.) as preliminary test. It was based on immunoassay by biochip array analyzer. Nine groups of drug abuse were screened: amphetamines, methamphetamines, cannabis, cocaine, opiates, barbiturates, methadone, benzodiazepines I (oxazepam) & II (lorazepam). Finally, confirmation of these drugs was performed by GC-MS. Blood samples were extracted by solid-phase extraction by $RapidTrace^{TM}$ (Zymark, U.S.A.). After trimethylsilyl (TMS) derivatization, eluates were analyzed to GC-MS. Total 49 drugs were investigated in this study including controlled drugs, antidepressants, 1st generation antihistamines, dextromethorphan, nalbuphine, ketamine, etc. For rapid detection, we developed the automated identification system. It was made up a new software, "DrugMan", modified Chemstation data analysis menu and newly developed macro modules. A series of peak selection, identification and reporting of the results were performed automatically by this system. Concentrations of alcohol in 275 blood samples were ranged from 0.011 to 0.249% (average, 0.119%). Among 149 blood samples, just six samples (4.0%) were showed positive results to the immunoassay: one methamphetamine and five benzodiazepines group I. By GC-MS confirmation, only benzodiazepines were detected and methamphetamine was not detected from immunoassay positive blood sample. Besides these drugs, 5 chlorpheniramines, dextromethorphan, diazepam, doxylamine, ibuprofen, lidocaine and topiramate were also detected in whole bloods by GC-MS. Conclusively, the frequency of drug abuse for Korean drivers was relatively low. There was none case which illegal drug was detected. However these results were limited to alcohol positive blood samples, so it is necessary to analyze more samples including alcohol negative blood.

'2019 한국형 조현병 약물치료 지침서'에 따른 조현병에서 동반증상 및 부작용의 치료 (Korean Treatment Guideline on Pharmacotherapy of Co-existing Symptoms and Antipsychotics-related Side Effects in Patients with Schizophrenia)

  • 윤제연;이정석;강시현;남범우;이승재;이승환;최준호;김찬형;정영철
    • 대한조현병학회지
    • /
    • 제22권2호
    • /
    • pp.21-33
    • /
    • 2019
  • Objectives: The current study covers a secondary revision of the guidelines for the pharmacotherapy of schizophrenia issued by the Korean Medication Algorithm for Schizophrenia (KMAP-SCZ) 2001, specifically for co-existing symptoms and antipsychotics-related side-effects in schizophrenia patients. Methods: An expert consensus regarding the strategies of pharmacotherapy for positive symptoms of schizophrenia, co-existing symptoms of schizophrenia, and side-effect of antipsychotics in patients with schizophrenia was retrieved by responses obtained using a 30-item questionnaire. Results: For the co-existing symptoms, agitation could be treated with oral or intramuscular injection of benzodiazepine or antipsychotics; depressive symptoms with atypical antipsychotics and adjunctive use of antidepressant; obsessive-compulsive symptoms with selective serotonin reuptake inhibitors and antipsychotics other than clozapine and olanzapine; negative symptoms with atypical antipsychotics or antidepressants; higher risk of suicide with clozapine; comorbid substance abuse with use of naltrexone or bupropion/varenicline, respectively. For the antipsychotics-related side effects, anticholinergics (extrapyramidal symptom), propranolol and benzodiazepine (akathisia), topiramate or metformin (weight gain), change of antipsychotics to aripiprazole (hyperprolactinemia and prolonged QTc) or clozapine (tardive dyskinesia) could be used. Conclusion: Updated pharmacotherapy strategies for co-existing symptoms and antipsychotics-related side effects in schizophrenia patients as presented in KMAP-SCZ 2019 could help effective clinical decision making of psychiatrists as a preferable option.